April 3, 2008 - Corgenix Medical Corp. has entered into an agreement with Randox Laboratories, a UK-based diagnostic company, in a partnership designed to expand the processing technology and distribution network of the Corgenix AspirinWorks platelets test kit product.
Under the terms of the agreement, the companies will collaborate in adapting the Corgenix AspirinWorks test to a format compatible with automated chemistry analyzers. The AspirinWorks test will be manufactured at Randox facilities in the UK, and the two companies will share global distribution rights.
According to Douglass Simpson, Corgenix President and CEO, "a key factor in the future success of the AspirinWorks product will be automation," and that he hopes this alliance will "result in a successful launch of the new product format next year."
AspirinWorks is a simple urine test that determines the effect of aspirin on platelets by measuring the level of thromboxane production (aspirin's target). The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient's aspirin therapy.
Unlike other platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the current AspirinWorks test only requires a urine sample that can be obtained in any doctor's office or patient service center, making the test easy for both physician and patient.
For more information: www.corgenix.com and www.randox.com